Last reviewed · How we verify
NCT04518553
Plasma Purification and Chronic Hepatitis B
NA trial testing active comarator using antiviral drug of nucleoside analogues in Chronic Hepatitis b in 230 participants. Status unknown.
1 September 2023
Quick facts
| Lead sponsor | Shanghai Pudong Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 230 |
| Start date | 23 March 2021 |
| Primary completion | 1 September 2023 |
| Estimated completion | 30 September 2023 |
Drugs / interventions tested
- active comarator using antiviral drug of nucleoside analogues — full drug profile →
- HA+purification
Conditions studied
- Chronic Hepatitis b — all drugs for Chronic Hepatitis b →
Sponsor
Shanghai Pudong Hospital
Who can join
Adults 18 to 75, any sex, with Chronic Hepatitis b. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To compare the efficacy of nucleoside analogues （HA） alone and plasma purification +HA in reducing HBV viral load.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04518553
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Hepatitis b
Currently open trials in the same condition.
- NCT07090759 — To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) · Phase 3 · recruiting
- NCT06989788 — A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, · Phase 1 · active not recruiting
- NCT06885710 — HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients · Phase 1 · recruiting
- NCT06671093 — Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B · Phase 1 · recruiting
- NCT06638320 — Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection · active not recruiting
Other Shanghai Pudong Hospital trials
Trials by the same sponsor.
- NCT07106034 — Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial · Phase 2 · not yet recruiting
- NCT06501183 — Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors · Phase 1 · recruiting
- NCT05559177 — An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer · EARLY_PHASE1 · unknown
- NCT05473884 — Lesion Preparation in Femoropopliteal Artery Occlusion Disease · unknown
- NCT05374772 — A Retrospective Study in Patients With Mild to Moderate COVID-19 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04518553 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Pudong Hospital
- Last refreshed: 17 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04518553.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing